Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)

Описание: This training program offers a comprehensive clinical overview of immune-related adverse events, specifically focusing on cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
It is designed for nurses and other allied healthcare professionals who are involved in the care of patients undergoing immunotherapy, providing them with the knowledge and skills necessary to effectively manage these complex conditions.

Learning Objectives:
Define CRS and ICANS:
Provide clear definitions and distinctions between CRS and ICANS.
Highlight the clinical significance of these conditions in the context of immunotherapy.
Discuss the Pathophysiology of CRS and ICANS:
Explain the underlying biological mechanisms and pathways involved in the development of CRS and ICANS.
Explore the role of immune effector cells and cytokines in these adverse events.
Recognize the Signs and Symptoms of CRS and ICANS:
Identify the key clinical manifestations and early warning signs of CRS and ICANS.
Differentiate between mild, moderate, and severe presentations of these syndromes.
Understand the Diagnosis, Grading, and Clinical Management of CRS and ICANS:
Outline the diagnostic criteria and grading systems used to assess the severity of CRS and ICANS.
Review evidence-based strategies for the clinical management and treatment of patients experiencing these adverse events.
Review Case Studies for CRS & ICANS to Support Learning:
Analyze real-world case studies to illustrate the practical application of knowledge in diagnosing and managing CRS and ICANS.
Discuss lessons learned and best practices derived from these case studiesThis training program offers a comprehensive clinical overview of immune-related adverse events, specifically focusing on CRS and ICANS. It is designed for nurses and other allied healthcare professionals who are involved in the care of patients undergoing immunotherapy, providing them with the knowledge and skills necessary to effectively manage these complex conditions.

Learning Objectives:
Define CRS and ICANS:
Provide clear definitions and distinctions between CRS and ICANS.
Highlight the clinical significance of these conditions in the context of immunotherapy.
Discuss the Pathophysiology of CRS and ICANS:
Explain the underlying biological mechanisms and pathways involved in the development of CRS and ICANS.
Explore the role of immune effector cells and cytokines in these adverse events.
Recognize the Signs and Symptoms of CRS and ICANS:
Identify the key clinical manifestations and early warning signs of CRS and ICANS.
Differentiate between mild, moderate, and severe presentations of these syndromes.
Understand the Diagnosis, Grading, and Clinical Management of CRS and ICANS:
Outline the diagnostic criteria and grading systems used to assess the severity of CRS and ICANS.
Review evidence-based strategies for the clinical management and treatment of patients experiencing these adverse events.
Review Case Studies for CRS & ICANS to Support Learning:
Analyze real-world case studies to illustrate the practical application of knowledge in diagnosing and managing CRS and ICANS.
Discuss lessons learned and best practices derived from these case studies

Sign up for dozens of relevant nurse training at this free self-study platform: https://hcpen-llscanada.talentlms.com/